Dr. Heibel believes in fiscally responsible development of therapeutics to benefit the public good. As the COO for Audacity Therapeutics, she applies her multi-disciplinary expertise as a scientist, program manager, and regulatory specialist with extensive knowledge of drug development and rare disease regulatory strategy. She co-leads the Commission on Financing a Public Benefit Biotechnology Industry, an initiative to develop a finance model that can support a new way of doing the biotech business to produce more medicines for more diseases at sustainable costs. She also serves as the Chief of Science and Regulatory Affairs at Haffner Associates where she works with Dr. Marlene Haffner, the preeminent expert in orphan drug regulatory affairs. Prior to working in the regulatory affairs field, she spent 13 years conducting preclinical and clinical research in a laboratory setting with a focus on rare, heritable diseases.
